Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and Sintilimab in Refractory Metastatic Colorectal Cancer
NCT04695470Phase 2Unknown
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, sintilimab in colorectal cancer (CRC). Status: unknown.
02
Drugs
fruquintinibsintilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04695470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695470.